On July 27, 2020, Kato, Mikiya; Imazu, Takuya published a patent.Electric Literature of 386704-04-7 The title of the patent was Preparation of indazole derivatives as RORγt inhibitors. And the patent contained the following:
Provided are compounds I [R1 = H, halo, alkyl, etc.; R2 = H, halo or alkyl; R3a, R3b = independently H, halo, alkyl, etc.; R4a, R4b = independently H, halo or alkyl; R5 = CO2H or CO2R21; R21 = alkyl or alkenyl; R6a, R6b = independently H or alkyl; R7 = H, halo, cyano, etc.; R8 = H, halo, cyano, etc.; R9 = halo, alkyl, alkoxy, etc.; R10 = halo; Xa = single bond, cycloalkylene or alkynylene; n = 1 or 2; p = 0-2; q = 0-3; ring A = aryl, heteroaryl, cycloalkyl, etc.; or their pharmaceutically acceptable sats]. Thus, compound II was prepared via DIAD-mediated reaction of 7-chloro-1H-indazole-4-carboxylic acid Me ester with (trans-4-(trifluoromethyl)cyclohexyl)methanol, hydrolysis, amidation with 2-(trans-4-(aminomethyl)cyclohexyl)acetic acid Me ester·HCl in the presence of HATU, and hydrolysis. In RORγt (retinoic acid receptor-related orphan receptor-γt) inhibition assay, the invention compounds, e.g., II, showed IC50 value of <300 nM. Compounds I are claimed useful for the treatment of autoimmune diseases or allergic diseases. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Electric Literature of 386704-04-7
The Article related to indazole preparation ror gamma t inhibitor, autoimmune allergic disease treatment indazole ror gamma t inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Electric Literature of 386704-04-7
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts